Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 2
2012 4
2013 7
2014 5
2015 6
2016 6
2017 3
2018 3
2019 11
2020 13
2021 10
2022 7
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial.
Kim KH, Lim SM, Ahn HK, Lee YG, Lee KW, Ahn MJ, Keam B, Kim HR, Lee HW, An HJ, Kim JS. Kim KH, et al. Among authors: an hj. Cancer Res Treat. 2024 Jan;56(1):37-47. doi: 10.4143/crt.2023.433. Epub 2023 Jul 20. Cancer Res Treat. 2024. PMID: 37475136 Free PMC article. Clinical Trial.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation.
Lee GJ, Kim H, Cho SS, Park HS, An HJ, Woo IS, Byun JH, Hong JH, Ko YH, Sun S, Won HS, Jin JY, Park JC, Kim IH, Roh SY, Shim BY. Lee GJ, et al. Among authors: an hj. J Gastric Cancer. 2023 Apr;23(2):315-327. doi: 10.5230/jgc.2023.23.e16. J Gastric Cancer. 2023. PMID: 37129155 Free PMC article.
Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy.
Lee JB, Park HS, Choi SJ, Heo SG, An HJ, Kim HR, Hong MH, Lim SM, Chang K, Quinn K, Odegaard J, Shim BY, Cho BC. Lee JB, et al. Among authors: an hj. Ther Adv Med Oncol. 2022 Dec 17;14:17588359221141761. doi: 10.1177/17588359221141761. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36544541 Free PMC article.
72 results